Turning the Titanic-Reference-Cited by-同舟云学术

Turning the Titanic

Published:2014-01-29 Issue:221 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Zerhouni Elias A.¹

Affiliation:

1. Elias A. Zerhouni is President of Global R&D, Sanofi, 75008 Paris, France, and former Director of the U.S. National Institutes of Health.

Abstract

The R&D engine must be redirected toward deciphering the natural histories of human diseases and using this knowledge to select therapeutic targets.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference6 articles.

1. Pharmaceutical Innovation Gets a Little Help from New Friends

2. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

3. Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease

4. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

5. “Rare mutation ignites race for cholesterol drug ” New York Times 9 July 2013;www.nytimes.com/2013/07/10/health/rare-mutation-prompts-race-for-cholesterol-drug.html?pagewanted=all&_r=0.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Targeting;Encyclopedia of Cell Biology;2023

2. Buprenorphine implants: a model for expedited development and approval of new drugs;Current Medical Research and Opinion;2020-11-24

3. Translatie als filosofisch programma;Algemeen Nederlands Tijdschrift voor Wijsbegeerte;2019-10-01

4. Recommendations toward a human pathway-based approach to disease research;Drug Discovery Today;2018-11

5. Public–private partnerships as enablers of progress in the fight against mental disorders: The example of the European Innovative Medicines Initiative;European Psychiatry;2018-04